Analysis Writedowns and growing pains ahead for Tilray 2.0, analyst says But Chris Damas of the BCMI Cannabis Report notes the Aphria-merged firm will command a strong presence in Europe's medical cannabis market Jared GnamMay 3, 2021
Canada Health Canada opens up CBD market with new hemp cultivar approvals With around a dozen new high-CBD hemp varieties approved, companies eye low-cost production and looser cannabidiol rules Jared GnamApril 21, 2021
Industry update Tilray reduces required shareholder vote count to 1/3 for Aphria merger The Canadian weed firm urges all shareholders to weigh in on the vote, which has been delayed to April 30 Jared GnamApril 16, 2021
Industry update Hexo touts Q2 earnings, eyes M&A Once its deal to buy Zenabis closes, Hexo says it will be close to top-2 in Canadian recreational weed sales Jared GnamMarch 18, 2021
Industry update Hexo to enter Europe with $265M Zenabis acquisition Hexo says the all-stock deal will gives it a top-3 spot in the Canadian cannabis market and a key foothold in Europe Jared GnamFebruary 16, 2021
Analysis Reddit traders send pot stocks to the moon — and back Cannabis stock spikes fueled by Reddit traders this week have little to do with fundamentals, says TradingView GM Pierce Crosby Jared GnamFebruary 12, 2021
Industry update Tilray stock soars 40% on UK supply deal with Grow Pharma The BC-based producer continues global expansion flurry since unveiling merger deal with Aphira Jared GnamFebruary 9, 2021
Industry update Tilray first company approved to sell medical cannabis in Portugal Propelled by its GMP-certified facility in Portugal, the BC-based producer says it now sells weed in 16 countries Jared GnamFebruary 1, 2021
Data Cannabis significantly reduces prescription opioid use: Tilray patient study In the first substitution study to track individual use over time, researchers found stark drops in use of opioids and other medications Nick LabaJanuary 22, 2021
Industry update Aphria stock hits 2-year high on record Q2 sales The firm's valuation is rocketing along with most pot stocks, but uncertainty remains if it can better capitalize on both domestic and international markets Nick LabaJanuary 14, 2021